Whole-exome sequencing identifies $GPSM1$ as a susceptibility gene for premature ovarian insufficiency

CURRENT STATUS: UNDER REVIEW

Journal of Ovarian Research  ▪ BMC

Xuzi Cai
The Third Affiliated Hospital of Southern Medical University

Huijiao Fu
The Third Affiliated Hospital of Southern Medical University

Yan Wang
The Third Affiliated Hospital of Southern Medical University

Qiwen Liu
The Third Affiliated Hospital of Sourth Medical University

Xuefeng Wang
The third affiliated hospital of southern medical university

douwangxuefeng@163.com Corresponding Author
ORCiD: https://orcid.org/0000-0003-2455-9442

DOI: 10.21203/rs.3.rs-18442/v1

SUBJECT AREAS
Cancer Biology

KEYWORDS
premature ovarian insufficiency, whole-exome sequencing, $GPSM1$, ovarian granulosa cell, cAMP-PKA-CREB pathway
Abstract

**Background** Genetic causes of premature ovarian insufficiency (POI) account for approximately 20~25% of patients. So far, only a few genes have been identified.

**Results** Here, we first identified the c.1840C>A on G-protein signaling modulator 1 (GPSM1) as a susceptibility locus for POI in 10 sporadic POI patients by whole-exome sequencing. The frequency of GPSM1 c.1840C>A was then verified as 3/20 in a POI sample of 20 patients (including the above 10 patients) by Sanger sequencing. RT-PCR and western blot analysis showed the expression of GPSM1 in rat ovaries was increased in the large antral follicle stage compared to the primordial follicle stage (P<0.01). The cell proliferation assay (CCK8) and flow cytometry suggested that the small-interfering RNA-induced silencing of Gpsm1 significantly increased apoptosis and decreased proliferation of rat ovarian granulosa cells (GCs) (P<0.01). Furthermore, suppression of Gpsm1 in GCs reduced levels of cAMP, PKAc, p-CREB as well as the ratio of Bcl-2/Bax, and increased the expression of Caspase-3 and Cleaved Caspase-3 (P<0.01).

**Conclusions** In summary, this study identified a susceptibility variant GPSM1 c.1840C>A of POI for the first time. Gpsm1 was related to rat follicle development, and silencing increased apoptosis and decreased proliferation in rat GCs, possibly through inhibition of the cAMP-PKA-CREB pathway. These findings facilitate the development of the early molecular diagnosis of POI.

**Introduction**

Premature ovarian insufficiency (POI) is a clinical syndrome characterized by the loss of ovarian activity before the age of 40 years, which results in hypergonadotropic hypogonadism.(1) It affects approximately 1% women under 40 years old(2). The opportunity to preserve fertility in women with POI is small, which has a negative impact on both the psychological and reproductive health of women of childbearing age. As women are marrying at a later age, infertility caused by POI is becoming a greater concern. Early detection of the high-risk population would allow for increased treatment options, and perhaps the POI-related infertility could be avoided. Research into the pathogenesis of POI is particularly important for molecular diagnosis and prevention.

Although most POI cases are idiopathic, genetic factors are considered to be one of the main causes
of POI(3), accounting for 20–25%(4). Currently, only several genes have been confirmed to be associated with the pathogenesis of POI, including FOXL2, BMP2, NOBOX, FIGLA, and GDF9(5). The screening and validation of POI candidate genes is a large task. Currently, most of the research on POI-pathogenesis genes is focused on pedigree studies(6, 7). However, POI presents with high genetic heterogeneity; each family or individual patient seems to be unique in the pathogenesis and there is no significant definitive pathogenic gene for POI. If common pathogenic mutations can be sought out in sporadic POI populations, more insight into the genetic changes of POI patients can be gained. In recent years, with the development and maturity of high-throughput sequencing technologies, whole-exome sequencing (WES) has been widely applied to explore new pathogenic genes of hereditary disease, and has been verified as an effective tool for research into genetic etiology(8–10).

In this study, we used WES to initially identify a POI susceptibility gene in unrelated Chinese women affected by POI. A functional study was then carried out using rat ovarian granulosa cells (GCs). The outcome of this study will provide insight into the potential application of genetic sequencing for molecular diagnosis, allowing for better health management (e.g., early detection and childbearing) for carriers of the deleterious susceptibility gene mutation.

**Results**

WES and Sanger sequencing identified heterozygous GPSM1 mutation in 3 POI patients

We performed WES on 10 POI patients to. The mean coverage of the target region is 99.8%. More than 98.76% of the target was covered at 20 × depth. We applied the following exome filtration procedure: total variants called in 10 patients and variants that are absent or with minor allele frequency less than 1% in the population public databases (dbSNP, 1000Genomes, and ExAC). After these filters, a total of 12 genes including 22 variants were retained: OR2T29 (c.26A > G), ANKRD36C (c.1265T > G), FRG1 (c.330G > T), PSPH (c.268G > A), PABPC3 (c.541G > A, c.691A > G, c.832C > T, c.859A > G, c.938C > T, c.956C > T), LMO7 (c.911G > A), TPSAB1 (c.422C > T), TBC1D26 (c.167A > C), CNN2 (c.629T > C, c.630G > A, c.632G > T, c.670G > A, c.680G > A, c.695C > A), DKKL1 (c.71T > G), SCUBE1 (c.1169C > G), and GPSM1 (c.1840C > A). All the above mutations presented as heterozygous. Details of all variants are listed in Table 1. Of these candidate genes, GPSM1 (G-protein signaling
modulator 1) sparked our interest. For GPM1 (c.1840C > A), the ExonicFunc. refGene, rs number, ExAC, 1000G(all), SIFT score, Plopyphen2 score were missense mutation, rs539775258, 0.000008446, 0.0002, 0.001, and 0.998, respectively. Protein alignments revealed the GPM1 p. Glu614Lys variant, located in the third G-protein regulatory (GPR) motif of the protein, affected an amino acid highly conserved among species (Fig. 1). Sanger sequencing confirmed that GPM1 (c.1840C > A) were heterozygous in 3/20 patients.

Table 1
Information about candidate gene (ND: no date)

| Gene | Chr | Transcription | Exon | Nucleotide change | dbSNP | 1000 genomes ExAC | Plopyphen2 | SIFT | Mutation predictions | LRT | Mutation Assessment | Genotype | Number of variant samples |
|------|-----|---------------|------|------------------|-------|-------------------|------------|------|---------------------|-----|---------------------|----------|------------------------|
| OR2T29 | Chr1 | NM_0 01004694 | 1 | c.26A > G | p.N9S | ND | ND | 0.000009122 | Benign | Deleterious | Probable harmful | Neutral | Medium | Heterozygous | 5 |
| ANKR D36C | Chr2 | NM_0 01310154 | 16 | c.126T > G | p.V422G | rs78715705 | ND | 0.0001 | ND | Deleterious | Probable harmful | ND | ND | Heterozygous | 4 |
| FRG1 | Chr4 | NM_0 014477 | 5 | c.330G > A | p.K110G | ND | ND | 0.009 | Deleterious | Disease causing | Deleterious | Medium | Heterozygous | 5 |
| SPSPH | Chr7 | NM_0 04577 | 5 | c.268G > A | p.G90S | rs75395437 | 0.0001 | ND | Deleterious | Disease causing | Deleterious | Medium | Heterozygous | 9 |
| PABP C3 | Chr13 | NM_0 030970 | 1 | c.541A > G | p.A181T | rs11210773 | 0.0007 | 0.001 | Deleterious | Disease causing | Disease causing | Medium | Heterozygous | 8 |
| PABP C3 | Chr13 | NM_0 030980 | 1 | c.691A > G | p.K231E | rs78826513 | ND | 0.002 | Deleterious | Disease causing | Disease causing | Unknown | Medium | Heterozygous | 9 |
| PABP C3 | Chr13 | NM_0 030981 | 1 | c.832G > T | p.R278C | rs78552667 | ND | 0.000 | Benign | Deleterious | Disease causing | Medium | Heterozygous | 9 |
| PABP C3 | Chr13 | NM_0 030981 | 1 | c.859A > G | p.R287G | rs201411821 | ND | 0.000 | Benign | Deleterious | Disease causing | Unknown | High | Heterozygous | 9 |
| PABP C3 | Chr13 | NM_0 030981 | 1 | c.938G > T | p.A313V | rs76994938 | 0.000 | 0.000 | Benign | Deleterious | Disease causing | Unknown | Neut | Heterozygous | 8 |
| PABP C3 | Chr13 | NM_0 030984 | 1 | c.95C > T | p.T319I | rs80261016 | ND | 0 | Benign | Deleterious | Disease causing | Medium | Low | Heterozygous | 9 |
| LMO7 | Chr13 | NM_0 01306080 | 10 | c.161G > A | p.R537K | rs142687160 | 0.009 | 0.003 | Benign | Deleterious | Disease causing | Deleterious | Neut | Heterozygous | 5 |
| TPSA B1 | Chr16 | NM_0 03294 | 4 | c.422C > T | p.T141I | rs1064781 | ND | 0.000 | Benign | Deleterious | Probable harmful | Neut | Neut | Heterozygous | 8 |
Increased level of GPSM1 in multi-follicle developed ovary

Multi-follicle development in immature rats was successfully promoted. The ovaries of the PMSG group were significantly enlarged, congestive, and multi-follicles developed compared to the NS group (Fig. 2A). The weight of the ovaries in the PMSG group increased significantly, about three times as much as the NS group (P < 0.01, Fig. 2B). A significant increase in GPSM1 mRNA and protein expression was observed in the PMSG group compared to the NS group, as demonstrated by RT-PCR and western blot analysis, respectively (P < 0.01, Fig. 2C, D).

Figure 2. The expression of GPSM1 in ovaries before and after multi-follicle development

A. Morphological changes of rat ovaries: a. Ovaries from NS-treated immature rats were light pink and normal in size; b. Ovaries from PMSG-primed immature rats were significantly enlarged, with
hyperemia and mulberry-like changes. B. The weight of the bilateral rat ovaries after treatment in the experimental group (PMSG group, n = 3) was significantly increased compared to the control group (NS group, n = 3) (** P < 0.01). C and D. The expression of GPSM1 detected by RT-PCR and western blot was up-regulated in the PMSG group (n = 3) compared to the NS group (n = 3) (** P < 0.01).

GPSM1 downregulated affects cell apoptosis and proliferation in rat GCs

GPSM1 was widely expressed in the rat ovaries (Fig. 3A), such as in oocytes and GCs in different follicle stages, luteal cells, and stromal cells. Considering the significant role of GCs in follicular development, we further investigated the role of GPSM1 in GCs. Three siRNAs targeting Gpsm1 (siRNA-1, siRNA-2, and siRNA-3) and a siRNA for a negative control (NC-siRNA) were designed and individually transfected into GCs. The results show that NC-siRNA had no significant effect on the expression of GPSM1, and siRNA-3 had the highest knockdown efficiency (> 70%) at both mRNA and protein levels (Fig. 3B, C); siRNA-3 was used in the following experiments. The CCK8 assay showed GCs in both groups were in a proliferative trend, but Gpsm1-knockdown markedly decreased proliferation at 48 h, 72 h, 96 h, and 120 h (P < 0.01, Fig. 3D). Flow cytometry analysis revealed that Gpsm1-knockdown significantly increased the apoptosis rate of GCs (P < 0.01, Fig. 3E, F).

Figure 3. The effect of silencing GPSM1 on GCs

A. The expression of GPSM1 in rat ovaries detected by immunohistochemistry. B and C. Silencing of Gpsm1 expression in GCs using siRNAs. RT-PCR (B) and western blot (C) analyses showed that Gpsm1-targeting siRNA-3 provided optimal depletion of GPSM1 in GCs compared to the siRNA-negative control (NC-siRNA) and blank control (**P < 0.01). D. Gpsm1-knockdown decreased the proliferation rate of GCs significantly 48 h, 72 h, 96 h, and 120 h after transfection with siRNA. GCs transfected with NC-siRNA or Gpsm1-siRNA were subjected to CCK8 analysis (**P < 0.01). E and F. Gpsm1-knockdown increased the apoptosis rate of GCs. GCs transfected with NC-siRNA or Gpsm1-siRNA were subjected to Annexin V-FITC/PI double staining and flow cytometric analysis (**P < 0.01).

Downregulating of Gpsm1 alters the expression of the cAMP-CREB-PKA signaling molecules in GCs

Next, we investigated the effect of Gpsm1-knockdown on intracellular signaling in rat GCs. RT-PCR
revealed that the cAMP level decreased concomitantly with down-regulation of Gpsm1 (P < 0.01, Fig. 4A). It is widely known the various effects of cAMP are achieved mainly through activation of cAMP-dependent protein kinase A (PKA). Unexpectedly, there was no significant difference in PKA mRNA expression between the two groups (P > 0.05, Fig. 4A). Therefore, we targeted PKAc, a catalytic subunit of PKA, protein levels for western blot analysis. The PKAc protein level was significantly reduced in the Gpsm1-silenced group compared to the NC group (P < 0.01, Fig. 4B). As some studies have reported that GPSM1 could regulate the phosphorylation of cAMP-response element binding protein (CREB) by mediating PKA(11), and p-CREB could regulate transcription of the apoptosis suppressor Bcl-2(12), the CREB, p-CREB, and Bcl-2 protein levels were assessed. Both the RNA and protein expression of p-CREB and Bcl-2 were attenuated in the Gpsm1-silenced group compared to the NC group (P < 0.01, Fig. 4), while CREB expression showed no significant difference (P > 0.05, Fig. 4). To calculate the ratio of Bcl-2/Bax, Bax was quantified; the results showed an elevation of RNA levels in the Gpsm1-silenced group (P < 0.01, Fig. 4A) but no difference between groups at the protein level (P > 0.05, Fig. 4B). However, the ratio of Bcl-2/Bax was noticeably decreased at both the RNA and protein levels. Finally, RNA and protein levels of Caspase-3, and protein levels of cleaved Caspase-3, were found to be elevated in the Gpsm1-silenced group (P < 0.01, Fig. 4).

Figure 4. Silencing of Gpsm1 alters the expression of the cAMP-CREB-PKA signaling molecules in GCs. After GCs were transfected with NC-siRNA and Gpsm1-siRNA, RT-PCR (A) and western blot (B) analyses were performed to measure the levels of GPSM1 and intracellular signaling molecules. The average results from three independent experiments are shown (**P < 0.01).

Discussion
From our study of 10 POI patients, we identified a novel POI susceptibility gene, GPSM1. The GPSM1 gene was reported in public expression databases to be expressed in multiple types of tissue and cell, especially in ovary (https://www.ncbi.nlm.nih.gov/gene/26086). It encodes activator of G protein signaling 3 (AGS3), which was identified as an evolutionarily conserved protein(13, 14) and to be associated with cell division(15), cell proliferation(16), differentiation(17), autophagy(18) and so on. AGS3 has a modular domain structure consisting of seven tetratricopeptide repeats (TPRs) and four G-
protein regulatory (GPR) motifs. It was a regulatory accessory protein of G-protein signaling which could bind preferentially to inactive Ga/o subunit complexed with guanine dinucleotide phosphate (GDP) at multiple GPR motif repeats(15, 19, 20). Thus, it could regulate the production of cAMP which is one of the most important second messengers in pathways of metabolism, apoptosis, proliferation and material transport. The heterozygous variant of GPSM1 c.1840C > A is a missense mutation occurring at the third GPR motif of ASG3, leading to a change in amino acid sequence, thus likely to be a highly pathogenic mutation. Sanger sequencing determined the frequency of GPSM1 c.1840C > A in the small POI sample of 20 patients to be 3/20. This suggested GPSM1 c.1840C > A might be involved in POI. To the best of our knowledge, this is the first report of GPSM1 c.1840C > A in POI patients.

Early studies(21, 22) have shown that at 24 h following PMSG treatment, the ovaries of rats presented with multiple follicular growth, and at 48 h, the follicular antrum was extremely large and the parietal granulosa cell layer became very thin. Here, we first explored the expression pattern of GPSM1 at different stages of ovarian growth in rats. The results showed that the expression of GPSM1 was significantly increased in the large antral follicle stage compared to the primordial follicle stage. This result indicated that GPSM1 might play an important role in follicular growth in rats.

The apoptosis of GCs and follicular atresia have been shown to play key roles in the pathogenesis of POI(3, 23). The mechanism by which GPSM1 regulates heterotrimeric G-proteins in GCs has yet to be elucidated. GPSM1, encoding AGS3, could compete with free G subunits for binding to Ga/o-GDP subunits, regulating downstream signal transduction pathways by inhibiting the Gi subunit. The Gi subunit directly inhibits adenylyl cyclase (AC) activity(24). That is how GPSM1 conducts signals, by activating AC to promote the synthesis of cAMP. Changes in cAMP levels are a common observation in the growth and maturation of GCs(25, 26). Thus, we initially postulated GPSM1 in GCs might play an important role in apoptosis by regulating the activation of cAMP pathways.

To verify this hypothesis, we first demonstrated the silencing of Gpsm1 induced GC apoptosis and inhibited proliferation. Furthermore, it was confirmed that the generation of cAMP was correlated to the expression of GPSM1 in rat GCs. Next, we explored the downstream signaling molecules of cAMP
in GCs. There was no decline in PKA levels, but PKAc decreased when GPSM1 was down-regulated, which suggested the subsequent signal transduction mediated by cAMP might not be transmitted by the change of PKA level, but probably by the level of PKAc, which is an active subunit decomposed from PKA. Concomitant with the reduction of PKAc, CREB, a target molecule of PKA, as well as an important mediator of multiple signal transduction pathways in GCs(27, 28), was found to be less phosphorylated in Gpsm1-knockdown cells. Bcl-2 is a well-known target of CREB(12), and was also reported as one of the important apoptosis suppressors in GCs(29). Bax-dependent apoptosis is a common pathway of cell death and the balance of Bcl-2 and Bax is a key determinant of the survival or death of GCs. As expected, the level of Bcl-2 and the ratio of Bcl-2/Bax were found to be markedly reduced after down-regulation of GPSM1. Finally, as apoptosis markers, Caspase-3 and cleaved Capase-3 showed an uptrend in Gpsm1-knockdown cells.

Conclusions
In summary, we first identified GPSM1 as a novel susceptibility gene for POI, and found it to be associated with follicular development in rats. Then, we confirmed the anti-apoptotic and proliferative functions of GPSM1 in rat GCs, and found that the possible mechanism of action might be through regulation of the Bcl-2/Bax ratio through cAMP-PKA-CREB signaling, which affects the activation of apoptosis protein, Caspase-3, ultimately determining the survival or death of GCs. While further studies are required to verify the results of this study, our findings shed light on the etiology of POI by providing new candidates and pathways to explore.

Methods
Ethics statement and patients
This study was approved by and performed in accordance with the Ethics Committee of Zhujiang Hospital of the Southern Medical University. All patients gave written informed consent for whole-exome sequencing
A total of 20 unrelated Han Chinese women were recruited. All had at least 6 months of amenorrhea before the age of 40, high FSH plasma levels (> 25 IU/mL) twice at least four weeks apart, and a normal 46 XX karyotype. Women having a background of pelvic surgery, anticancer treatment, ovarian infection, autoimmune disease, and/or positive family history were excluded from this study.
The clinical characteristics of 20 POI patients are summarized in detail in Supplemental Table 1.

WES and bioinformatics analysis
Genomic DNA from patients was extracted from peripheral blood leukocytes using standard procedures. WES was performed on patients 1-10 using the SureSelect Human All Exon V6 / V6 + UTR Kit (Agilent Technologies, Santa Clara, CA, USA) on the NextSeq 500 platform from Illumina (San Diego, CA USA). The raw image files were processed into variants with high reliability through several steps of base calling, quality control, alignment, and calibration. Basic sequencing information, including bases, length of reads, depth, and coverage is available in Supplemental Table 2. Single nucleotide variants and indels were then annotated using ANNOVAR. Variants fulfilling the following criteria were retained: (1) absent or rare variants (frequency < 0.01) in the dbSNP, 1000 Genomes Project, and Exome Aggregation Consortium databases; (2) protein structure-altering variants with pathogenicity predicted by SIFT, PolyPhen2, Mutation Assessor, and Mutation Taster.

Validation of mutation by Sanger sequencing
The mutations identified by WES and selected after literature reference were verified by Sanger sequencing in all 20 patients. Primers were designed to amplify the target region flanking the mutation site and are listed in Supplemental Table 3. Purified PCR products were sequenced on an ABI 3730XL (Applied Biosystems, USA) using the BigDye 3.1 Terminator Sequencing Kit (Applied Biosystems, USA) following the manufacturer's protocol.

Induction of follicle development and isolation of ovaries in rats
To stimulate follicular growth, immature female Sprague-Dawley (SD) Rats (24–25 days) were intraperitoneally injected with pregnant mare serum gonadotropin (PMSG, 40 IU/rat) (Ningbo Second Hormone Plant, Zhejiang, China). The experimental group (PMSG group, n = 3) was treated as above. The control group (NS group, n = 3) was intraperitoneally injected with an equal volume of normal saline (NS). Rats were sacrificed 48 h later, and the ovaries were removed immediately and cleaned with phosphate-buffered saline (PBS) for subsequent assays. One ovary of each rat (n = 6) was used for RT-PCR, and one for western blotting.

Immunohistochemistry
Ovaries of mature female SD rats (12 weeks) were removed, formalin fixed, paraffin embedded,
sectioned (4 µm), deparaffinized, and rehydrated. Endogenous peroxidase activity was blocked by incubation of the sections with 3% H₂O₂ for 15 min. Nonspecific binding was blocked with 5% bovine serum albumin (CWBO, Jiangsu, China) for 30 min. After washing, sections were incubated overnight at 4°C with an antibody against GPSM1 (1:200, Proteintech, Wuhan, China), followed by incubation with a biotinylated secondary antibody (1:1000) for 1 h at room temperature. After washing, the antibody complexes were visualized with a DAB Kit (ZSGB-BIO, Shanghai, China) according to the manufacturer's instructions. The sections were counterstained with hematoxylin, then dehydrated, and mounted.

**Isolation and culture of primary rat GCs**
PMSG was intraperitoneally injected into immature female SD rats aged 24–25 days at 40 IU/rat. The rats were sacrificed 48 h later and the ovaries were immediately removed. After washing with PBS, the ovaries were placed in DMEM/F12 medium. GCs were released from the ovarian follicles into the medium by a syringe needle under an anatomic microscope, and then purified by filtration with a 200-µm stainless steel mesh. The isolated GCs were centrifuged at 1000 × g for 5 min and then resuspended in medium. The GCs were seeded in 6-well plates (1 × 10⁶ cells/well) and cultured in DMEM/F12 containing 1% Penicillin/Streptomycin and 15% fetal bovine serum at 37 °C with 5% CO₂ for 48 h to allow cells to attach.

**Transfection**
Synthetic small-interfering RNAs (siRNAs) were purchased from Sangon Biotech (Shanghai). The sequences of Gpsm1-siRNA were 5′-CCUGCGGACCUGUCAUUTT-3′, 5′-GCCUAUGGCAACCUGGUATT-3′, and 5′-CCGAUUCGAUGAGGCAAUUTT-3′, named siRNA-1, siRNA-2, and siRNA-3, respectively. The sequence of siRNA for the negative control was 5′-UUCUCCGAACGUGUCACGUTT-3′, named NC-siRNA. The siRNAs were delivered into the cells with Lipofectamine 3000 (Life Technology, Invitrogen, USA) according to the protocols supplied. The RNA and protein samples were collected 48 h and 72 h after transfection, respectively.

**RNA isolation and RT-PCR**
Total RNA was isolated from ovarian tissues or cultured GCs using TRizol reagent (TaKaRa, Japan)
according to the manufacturer’s instructions. The first-strand cDNA for total RNA was synthesized using PrimeScript™ RT Reagent Kit with gDNA Eraser (TaKaRa, Japan). The expression levels of mRNA were detected by TB Green Premix Ex Taq II (TaKaRa, Japan) on a Bio-Rad Real-Time PCR system (Bio-Rad Inc, USA). Gapdh was used as the internal mRNA control. Target gene expression was determined using the \(2^{-\Delta\Delta C_{\text{t}}}\) method. The primer sequences for amplification are listed in Supplemental Table 4.

**Western blot analysis**

Total proteins were extracted from ovarian tissues or cultured GCs using RIPA Lysis Buffer (Beyotime Biotechnology, Shanghai, China) containing 1% phosphatase inhibitor and 1% protease inhibitor. The protein samples (15 µg) were loaded onto the sodium dodecyl sulfate polyacrylamide gel for electrophoresis, and then transferred to polyvinylidene difluoride membranes (Merck Millipore, Germany). After blocking in 5% non-fat milk at room temperature for 2 h, primary antibodies against GAPDH (1:500, Proteintech, Wuhan, China), GPSM1 (1:1000, Proteintech, Wuhan, China), PKAc (1:1000, Cell Signal, Beverly, MA, USA), CREB (1:1000, Cell Signal, Beverly, MA, USA), p-CREB (1:1000, Abcam, Cambridge, UK), Bcl-2 (1:1000, AbSci, WA, USA), Bax (1:1000, Proteintech, Wuhan, China), Caspase-3 (1:1000, Cell Signal, Beverly, MA, USA), and cleaved caspase-3 (1:1000, Cell Signal, Beverly, MA, USA) were incubated at 4°C overnight. The membranes were then incubated with secondary antibodies (1:500, Proteintech, Wuhan, China) for 1 h at room temperature. ECL detection reagent (Merck Millipore, Billerica, MA, USA) was used to visualize the bands. All experiments were repeated at least 3 separate times.

**Cell Counting Kit-8 (CCK8) assay**

Transfected GCs (2 × 10³) were plated into a 96-well plate. At 24, 48, 72, 96, and 120 h, cells were treated with 10 µL CCK-8 solution (Corning, Beijing, China) per well. The absorbance value (OD value) of each well was measured at 450 nm on a microplate reader after incubation at 37°C for 2 h. Each group was established in 5 wells. The proliferation rate was calculated and the cell proliferation curve was drawn. All tests were repeated at least 3 times.

\[
\text{Proliferation rate (%) = } \frac{\text{mean OD value at detection time point} - \text{OD value in blank group}}{\text{mean 24 h OD value} - \text{24 h OD value in blank group}}
\]

**Flow cytometry-based annexin/ propidium iodide (PI) assay**
GCs seeded in 6-well plates were transfected with siRNA and cultured for 48 h. Then $1 \times 10^6$ cells were collected, washed twice with ice-cold PBS, and resuspended in binding buffer containing Annexin V-FITC and PI. After incubating for 30 min in the dark, cells were analyzed using a BD FACSVerse flow cytometer system (BD Biosciences, USA) equipped with BD FACSuite software.

**Statistical analysis**
All data were analyzed using SPSS software (Version 22.0, SPSS Inc., Chicago, USA), and the results are presented as mean ± SEM using at least 3 independent experiments. An unpaired Student t-test was performed when comparing two groups and one-way ANOVA was performed when comparing more than two groups. A P value of 0.05 or less was considered statistically significant (*P < 0.05, **P < 0.01).

**Abbreviations**
POI
premature ovarian insufficiency
GPSM1
G protein signaling modulator 1
GCs
granulosa cells
RT-PCR
Real Time-Polymerase Chain Reaction
CCK8
Cell counting kit 8
siRNA
small interference RNA
WES
whole-exome sequencing
FSH
follicle-stimulating hormone
SNV
single nucleotide variants
SD
Sprague-Dawley
PMSG
pregnant mare serum gonadotropin
NS
normal saline
PBS
phosphate-buffered saline
AGS3
G protein signaling 3

Declarations

Ethics approval and consent to participate

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Zhujiang Hospital of the Southern Medical University. Written informed consent was obtained from individual or guardian participants.

Consent for publication

Written informed consent for publication was obtained from all participant.

Availability of date and materials

The raw data of WES required to reproduce these findings cannot be shared at this time as the data also forms part of an ongoing study. Single nucleotide variants and indels were annotated using ANNOVAR (http://www.openbioinformatics.org/annovar/). The variants were analysed using dbSNP (http://www.ncbi.nlm.nih.gov/snp/), 1000 Genomes Project (1000g, http://browser.1000genomes.org/index.html), and Exome Aggregation Consortium databases (ExAC, http://exac.broadinstitute.org/).

Competing interests

The authors declare that they have no competing interests.

Finding
This study was supported by the Science and Technology Planning Project of Guangdong province, China [2017A020214012] and Natural Science Foundation of Guangdong Province, China [2019A1515010452].

**Authors' contributions**

Xuzi Cai and Xuefeng Wang conceived and designed the study. Xuzi Cai and Huijiao Fu performed the experiments. Yan Wang and Qiwen Liu analyzed and interpreted the patient data regarding POI. Xuzi Cai wrote the paper. Xuefeng Wang reviewed and edited the manuscript. All authors read and approved the manuscript.

**Acknowledgments**

We appreciated all patients for their participation.

**References**

1. European Society For Human Reproduction And Embryology ESHRE Guideline Group. On POI WL, M D, R A, J B, D B, B C, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Human reproduction (Oxford, England) (Hum. Reprod.). 2016;31(5):926-37. https://www.ncbi.nlm.nih.gov/pubmed/27008889

2. JL L, P M, MF S, EB G, N S. Premature menopause in a multi-ethnic population study of the menopause transition. Human reproduction (Oxford, England) (Hum. Reprod.). 2003;18(1):199-206. Premature menopause in a multi-ethnic population study of the menopause transition. Human reproduction

3. LM N. Clinical practice. Primary ovarian insufficiency. The New England journal of medicine (N. Engl. J. Med.). 2009;360(6):606-14. https://www.ncbi.nlm.nih.gov/pubmed/19196677

4. CK W. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clinical endocrinology (Clin. Endocrinol. (Oxf)). 2008;68(4):499-
5. Y Q, X J, JL S, ZJ C. Genetics of primary ovarian insufficiency: new developments and opportunities. Human reproduction update (Hum. Reprod. Update). 2015;21(6):787-808. https://www.ncbi.nlm.nih.gov/pubmed/26243799

6. CC, ME, LC P, HE M, RA V, PL. A homozygous donor splice-site mutation in the meiotic gene MSH4 causes primary ovarian insufficiency. Human molecular genetics (Hum. Mol. Genet.). 2017;26(16):3161-6. https://www.ncbi.nlm.nih.gov/pubmed/28541421

7. PS, NZ, ST, YG, LC, JS, et al. A Biallelic Mutation in the Homologous Recombination Repair Gene SPIDR Is Associated With Human Gonadal Dysgenesis. The Journal of clinical endocrinology and metabolism (J. Clin. Endocrinol. Metab.). 2017;102(2):681-8. https://www.ncbi.nlm.nih.gov/pubmed/27967308

8. SC, VA A, EL, PA O, JL B, KO, et al. Mutant cohesin in premature ovarian failure.; 2014. p. 943-9. https://www.ncbi.nlm.nih.gov/pubmed/24597867

9. de Vries L, DM B, PS, IL, ST, LB. Exome sequencing reveals SYCE1 mutation associated with autosomal recessive primary ovarian insufficiency. The Journal of clinical endocrinology and metabolism (J. Clin. Endocrinol. Metab.). 2014;99(10):E2129-32. https://www.ncbi.nlm.nih.gov/pubmed/25062452

10. DJ F, LC P, YC S, de Jesús Rodríguez A, HE M, KM J, et al. Next generation sequencing in women affected by nonsyndromic premature ovarian failure displays new potential causative genes and mutations. Fertility and sterility (Fertil. Steril.). 2015;104(1):154-62. https://www.ncbi.nlm.nih.gov/pubmed/25989972

11. WW, QL, FZ, ZY, YW, TL, et al. Increased expression of AGS3 in rat brain cortex after traumatic brain injury. Journal of neuroscience research (J. Neurosci. Res.). 2013;91(5):726-36. https://www.ncbi.nlm.nih.gov/pubmed/23404409
12. JM S, DM B, TC C. Identification of a membrane Ig-induced p38 mitogen-activated protein kinase module that regulates cAMP response element binding protein phosphorylation and transcriptional activation in CH31 B cell lymphomas.; 2000. p. 2311-9. https://www.ncbi.nlm.nih.gov/pubmed/10679065

13. MJ C, A T, C M, JS L, X X, H F, et al. Genetic screens in yeast to identify mammalian nonreceptor modulators of G-protein signaling. Nature biotechnology (Nat. Biotechnol.). 1999;17(9):878-83. https://www.ncbi.nlm.nih.gov/pubmed/10471929

14. MJ C, A T, ML B, E D, SM L. Receptor-independent activators of heterotrimeric G-proteins. Life sciences (Life Sci.). 2001;68(19-20):2301-8. https://www.ncbi.nlm.nih.gov/pubmed/11358340

15. JB B, MJ C, M S, SM L. AGS proteins: receptor-independent activators of G-protein signaling. Trends in pharmacological sciences (Trends Pharmacol. Sci.). 2005;26(9):470-6. https://www.ncbi.nlm.nih.gov/pubmed/16084602

16. R N, JB B, G J, M K, T A, F Q, et al. Activator of G protein signaling 3 promotes epithelial cell proliferation in PKD. Journal of the American Society of Nephrology: JASN (J. Am. Soc. Nephrol.). 2010;21(8):1275-80. https://www.ncbi.nlm.nih.gov/pubmed/20488951

17. J X, M L, Q S, G F, D H, X L, et al. AGS3 is involved in TNF-α medicated osteogenic differentiation of human dental pulp stem cells. Differentiation; research in biological diversity (Differentiation). 2015;89(5):128-36. https://www.ncbi.nlm.nih.gov/pubmed/26143356

18. M G, J E, MG F, P G. A GDI (AGS3) and a GEF (GIV) regulate autophagy by balancing G protein activity and growth factor signals. Molecular biology of the cell (Mol. Biol. Cell). 2011;22(5):673-86. https://www.ncbi.nlm.nih.gov/pubmed/21209316

19. JB B, AV S, SM L. Mechanistic pathways and biological roles for receptor-independent
activators of G-protein signaling. Pharmacology & therapeutics (Pharmacol. Ther.).
2007;113(3):488-506.https://www.ncbi.nlm.nih.gov/pubmed/17240454

20. JB B, SM L. Activators of G protein signaling exhibit broad functionality and define a
distinct core signaling triad. Molecular pharmacology (Mol. Pharmacol.).
2014;85(3):388-96.https://www.ncbi.nlm.nih.gov/pubmed/24302560

21. NE, KA, NK. The selective prostaglandin EP4 agonist, APS-999 Na, induces follicular
growth and maturation in the rat ovary. European journal of endocrinology (Eur. J.
Endocrinol.). 2005;152(2):315-23.https://www.ncbi.nlm.nih.gov/pubmed/15745941

22. SA G, MH P, HJ R, RK V. Expression of 17 beta-hydroxysteroid dehydrogenase in the
rat ovary during follicular development and luteinization induced with pregnant mare
serum gonadotrophin and human chorionic gonadotrophin. The Journal of
endocrinology (J. Endocrinol.). 1994;140(3):409-17.https://www.ncbi.nlm.nih.gov/pubmed/8182368

23. FM, NI, NM, SO. Follicular growth and atresia in mammalian ovaries: regulation by
survival and death of granulosa cells. The Journal of reproduction and development
(J. Reprod. Dev.). 2012;58(1):44-50.https://www.ncbi.nlm.nih.gov/pubmed/22450284

24. DC, MI, JM E. Functional properties of Ca2+-inhibitable type 5 and type 6 adenyllyl
cyclases and role of Ca2+ increase in the inhibition of intracellular cAMP content.
Cellular signalling (Cell. Signal.). 1999;11(9):651-63.https://www.ncbi.nlm.nih.gov/pubmed/15745941

25. PD J, DJ T, DA H, SL, KP M. Apoptosis in bovine granulosa cells in relation to steroid
synthesis, cyclic adenosine 3',5'-monophosphate response to follicle-stimulating
hormone and luteinizing hormone, and follicular atresia. Biology of reproduction
(Biol. Reprod.). 1994;51(5):934-44.https://www.ncbi.nlm.nih.gov/pubmed/7849196

26. JS R. Perspective: the ovarian follicle--a perspective in 2001. Endocrinology
27. L F, HM C, JC C, PC L, YP S. Nitric oxide and cGMP induce COX-2 expression and PGE2 production in human granulosa cells through CREB signaling pathway. The Journal of clinical endocrinology and metabolism (J. Clin. Endocrinol. Metab.). 2015;100(2):E262-9. https://www.ncbi.nlm.nih.gov/pubmed/25423567

28. CK M, KE M. The LIM domain protein FHL2 interacts with the NR5A family of nuclear receptors and CREB to activate the inhibin-α subunit gene in ovarian granulosa cells. Molecular endocrinology (Baltimore, Md.) (Mol. Endocrinol.). 2012;26(8):1278-90. https://www.ncbi.nlm.nih.gov/pubmed/22734036

29. R D, L N, G L, S B, ML C, AM V, et al. Evidence of apoptosis in human primordial and primary follicles. Human reproduction (Oxford, England) (Hum. Reprod.). 2003;18(12):2678-82. https://www.ncbi.nlm.nih.gov/pubmed/14645191

Figures
Figure 1

Hotspot and conservation sites of GPSM1 Q614K. A. Functional domain information of Glu614Lys (Q614K) in protein GPSM1. B. Conservation analysis of GPSM1 Q614K among different species.
The expression of GPSM1 in ovaries before and after multi-follicle development. A. Morphological changes of rat ovaries: a. Ovaries from NS-treated immature rats were light pink and normal in size; b. Ovaries from PMSG-primed immature rats were significantly enlarged, with hyperemia and mulberry-like changes. B. The weight of the bilateral rat ovaries after treatment in the experimental group (PMSG group, n=3) was significantly increased compared to the control group (NS group, n=3) (** P<0.01). C and D. The expression of GPSM1 detected by RT-PCR and western blot was up-regulated in the PMSG group (n=3) compared to the NS group (n=3) (** P<0.01).
Figure 3

The effect of silencing GPSM1 on GCs. A. The expression of GPSM1 in rat ovaries detected by immunohistochemistry. B and C. Silencing of Gpsm1 expression in GCs using siRNAs. RT-PCR (B) and western blot (C) analyses showed that Gpsm1-targeting siRNA-3 provided optimal depletion of GPSM1 in GCs compared to the siRNA-negative control (NC-siRNA) and blank control (**P<0.01). D. Gpsm1-knockdown decreased the proliferation rate of GCs significantly 48 h, 72 h, 96 h, and 120 h after transfection with siRNA. GCs transfected with NC-siRNA or Gpsm1-siRNA were subjected to CCK8 analysis (**P<0.01). E and F. Gpsm1-knockdown increased the apoptosis rate of GCs. GCs transfected with NC-siRNA or Gpsm1-siRNA were subjected to Annexin V-FITC/PI double staining and flow cytometric analysis (**P<0.01).
Silencing of Gpsm1 alters the expression of the cAMP-CREB-PKA signaling molecules in GCs. After GCs were transfected with NC-siRNA and Gpsm1-siRNA, RT-PCR (A) and western blot (B) analyses were performed to measure the levels of GPSM1 and intracellular signaling molecules. The average results from three independent experiments are shown (**P<0.01).

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

Supplemental File.docx